NCT06694636Recruiting
Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 19 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Patients who met the inclusion criteria were treated with endovascular radiofrequency ablation and desympathetic nerve surgery. After enrollment, endovascular radiofrequency ablation and desympathetic surgery were performed. After radiofrequency ablation, the safety and efficacy of follow-up treatment will be carried out every 1 month or so, including blood routine, liver and kidney function, tumor indicators, abdominal CT/magnetic resonance, etc.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- First submitted
- 24 Jul 2024
- Start date
- 1 Feb 2024
- Primary completion date
- 1 Feb 2026
- Lead sponsor
- Zhongda Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06694636
What you commit to
- Study type: Interventional
- Planned participants: 5
- From 1 Feb 2024 to the primary completion date, 1 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Not suitable for ablation surgery
Other illness
- Mixed liver cancer
- Obvious bleeding tendencies and hematologic diseases
- Acute or severe systemic infection;
- Stroke or transient ischemic attack (TIA) within two weeks;
- Acute coronary syndrome within two weeks;
Other
- Pregnant, lactating and planning to become pregnant
- Orthostatic hypotension
- Intestinal obstruction
- Evaluated to be not suitable for this trial by investigators
Who the study is looking for
- Clinically or pathologically confirmed hepatocellular carcinoma (HCC)
- Locally progressed or distant metastatic unresectable advanced HCC
- Progressed after second-line therapy
- Agree to participate in the study and sign the informed consent form
Age in the registry: 25 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongda Hospital Coordinator of this site? Confirm its status | Nanjing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.